EO2401 (E) peptide immunotherapy + nivolumab (N) +/- bevacizumab (B) in recurrent glioblastoma (GB): EOGBM1-18/ROSALIE.
Year: 2023
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Wolfgang Wick, Ahmed Idbaih, Maria Vieito, François Ghiringhelli, Agostina Stradella, Ghazaleh Tabatabai, Michael C. Burger, Iris Mildenberger, Ulrich Herrlinger, Patrick Y. Wen, Mehdi Touat, Antje Wick, Macarena González, Alice Hervieu, Marta Gil-Martin, Mirjam Renovanz, Ana Maia, Christophe Bonny, Jan Fagerberg, David A. Reardon
Institutions: German Cancer Research Center, University Hospital Heidelberg, Sorbonne Université, Assistance Publique – Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Institut du Cerveau, Vall d'Hebron Hospital Universitari, Centre Georges François Leclerc, Institut Català d'Oncologia, Universitätsklinikum Tübingen, Goethe University Frankfurt, University Hospital Frankfurt, Medizinische Fakultät Mannheim, University Hospital Bonn, Dana-Farber Cancer Institute, University of Tübingen, Enterome (France)
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4379337243